27423449|t|Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
27423449|a|New chemotherapeutic regimens have improved survival for stage IV pancreatic ductal adenocarcinoma and occasionally major response of liver metastases can be observed. Aim of this work is to analyze the outcomes of patients undergoing primary chemotherapy for liver metastases from pancreatic cancer and to evaluate the results of surgical resection. Retrospective analysis. patients with extra-hepatic metastases, patients with Eastern Cooperative Oncology Group performance status â‰¥3, patients undergoing supportive care alone. 127 patients were identified. Liver metastases were unilobar in 28.5% of patients. Chemotherapy regimens included gemcitabine alone or in association with other agents (44%), oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX 8%), and cisplatin, gemcitabine plus capecitabine and epirubicin (PEXG) or capecitabine and docetaxel (PDXG) or epirubicin and fluorouracil (PEFG) (48%). 56 patients (44%) had a complete (7%) or partial response (37%). surgical resection was carried out in 11 patients (8.5%). Median overall survival was 11 months for the entire cohort and 15 months for those with partial / complete response. In this sub-group median survival was significantly longer (46 versus 11 months) for patients undergoing resection (P < 0.0001). Independent predictors of overall survival were chemotherapy with multiple agents (HR: 0.512), surgical resection (HR: 0.360), >5 liver metastases at diagnosis (HR: 3.515), and CA 19.9 reduction < 50% of baseline value (HR: 2.708). Surgical resection of primary pancreatic tumor with or without residual liver disease can be considered in selected cases after primary chemotherapy and it is associated with improved survival.
27423449	11	15	role	T077	C1705810
27423449	20	38	surgical resection	T061	C0728940
27423449	42	50	patients	T101	C0030705
27423449	56	73	pancreatic cancer	T191	C0030297
27423449	79	95	liver metastases	T191	C0494165
27423449	110	122	chemotherapy	T061	C3665472
27423449	124	127	New	T080	C0205314
27423449	128	153	chemotherapeutic regimens	T061	C0392920
27423449	168	176	survival	T169	C0220921
27423449	181	189	stage IV	T170	C0441772
27423449	190	222	pancreatic ductal adenocarcinoma	T191	C1335302
27423449	246	254	response	T033	C1704632
27423449	258	274	liver metastases	T191	C0494165
27423449	327	335	outcomes	T080	C0085415
27423449	339	347	patients	T101	C0030705
27423449	359	366	primary	T080	C0205225
27423449	367	379	chemotherapy	T061	C3665472
27423449	384	400	liver metastases	T191	C0494165
27423449	406	423	pancreatic cancer	T191	C0030297
27423449	431	439	evaluate	T058	C0220825
27423449	444	451	results	T034	C0456984
27423449	455	473	surgical resection	T061	C0728940
27423449	475	497	Retrospective analysis	T062	C0035363
27423449	499	507	patients	T101	C0030705
27423449	513	526	extra-hepatic	T029	C0205054
27423449	527	537	metastases	T191	C0027627
27423449	539	547	patients	T101	C0030705
27423449	553	606	Eastern Cooperative Oncology Group performance status	T201	C1520224
27423449	611	619	patients	T101	C0030705
27423449	631	646	supportive care	T061	C0344211
27423449	658	666	patients	T101	C0030705
27423449	684	700	Liver metastases	T191	C0494165
27423449	727	735	patients	T101	C0030705
27423449	737	758	Chemotherapy regimens	T061	C0392920
27423449	768	779	gemcitabine	T114,T121	C0045093
27423449	792	808	association with	T080	C0332281
27423449	815	821	agents	T120	C0450442
27423449	829	840	oxaliplatin	T109,T121	C0069717
27423449	842	852	irinotecan	T109,T121	C0123931
27423449	854	866	fluorouracil	T114,T121	C0016360
27423449	871	881	leucovorin	T109,T121,T127	C0023413
27423449	883	893	FOLFIRINOX	T061	C0879464
27423449	903	912	cisplatin	T121,T197	C0008838
27423449	914	925	gemcitabine	T114,T121	C0045093
27423449	931	943	capecitabine	T114,T121	C0671970
27423449	948	958	epirubicin	T109,T121	C0014582
27423449	960	964	PEXG	T061	C0392920
27423449	969	981	capecitabine	T114,T121	C0671970
27423449	986	995	docetaxel	T109,T121	C0246415
27423449	997	1001	PDXG	T061	C0392920
27423449	1006	1016	epirubicin	T109,T121	C0014582
27423449	1021	1033	fluorouracil	T114,T121	C0016360
27423449	1035	1039	PEFG	T061	C0392920
27423449	1051	1059	patients	T101	C0030705
27423449	1072	1080	complete	T080	C0205197
27423449	1089	1096	partial	T081	C0728938
27423449	1097	1105	response	T033	C1704632
27423449	1113	1131	surgical resection	T061	C0728940
27423449	1154	1162	patients	T101	C0030705
27423449	1171	1177	Median	T081	C0876920
27423449	1178	1185	overall	T080	C1561607
27423449	1186	1194	survival	T169	C0220921
27423449	1202	1208	months	T079	C0439231
27423449	1224	1230	cohort	T098	C0599755
27423449	1238	1244	months	T079	C0439231
27423449	1260	1267	partial	T081	C0728938
27423449	1270	1278	complete	T080	C0205197
27423449	1279	1287	response	T033	C1704632
27423449	1297	1306	sub-group	T185	C1515021
27423449	1307	1313	median	T081	C0876920
27423449	1314	1322	survival	T169	C0220921
27423449	1327	1340	significantly	T078	C0750502
27423449	1362	1368	months	T079	C0439231
27423449	1374	1382	patients	T101	C0030705
27423449	1394	1403	resection	T061	C0728940
27423449	1418	1429	Independent	T078	C0085862
27423449	1430	1440	predictors	T078	C2698872
27423449	1444	1451	overall	T080	C1561607
27423449	1452	1460	survival	T169	C0220921
27423449	1466	1478	chemotherapy	T061	C3665472
27423449	1484	1492	multiple	T081	C0439064
27423449	1493	1499	agents	T120	C0450442
27423449	1501	1503	HR	T081	C2985465
27423449	1513	1531	surgical resection	T061	C0728940
27423449	1533	1535	HR	T081	C2985465
27423449	1548	1564	liver metastases	T191	C0494165
27423449	1568	1577	diagnosis	T033	C0011900
27423449	1579	1581	HR	T081	C2985465
27423449	1595	1602	CA 19.9	T059	C0201551
27423449	1603	1612	reduction	T080	C0392756
27423449	1622	1636	baseline value	T081	C1442488
27423449	1638	1640	HR	T081	C2985465
27423449	1650	1668	Surgical resection	T061	C0728940
27423449	1672	1679	primary	T080	C0205225
27423449	1680	1696	pancreatic tumor	T191	C0030297
27423449	1713	1721	residual	T080	C1609982
27423449	1722	1735	liver disease	T047	C0023895
27423449	1778	1785	primary	T080	C0205225
27423449	1786	1798	chemotherapy	T061	C3665472
27423449	1809	1824	associated with	T080	C0332281
27423449	1825	1833	improved	T033	C0184511
27423449	1834	1842	survival	T169	C0220921